ICYMI, some of this week’s featured content includes how to provide the best care to your gender and sexual minority patients, updates in the pipeline for psoriasis, a new drug on the horizon for cSCC, plus more.
Dermatologists are divided over concerns of spironolactone being underused in women and patients taking isotretinoin being overmonitored.
AxisBiotix-Ps food supplement shows positive results in a recent consumer study evaluating its efficacy for psoriasis treatment.
The SaltFacial achieves promising results in treating multiple skin conditions.
Secukinumab (Cosentyx, Novartis) has received FDA approval for the treatment of children and adolescents with moderate to severe plaque psoriasis.
Each month, Dermatology Times® features a roundup of products trending in skin care. Click here to find out what products are trending for the month of June.
The anti–PD-L1, fully human monoclonal antibody cosibelimab will be examined in a cohort of patients with metastatic cutaneous squamous cell carcinoma (cSCC) as part of an ongoing phase 1 study.
Trichoscopy, which is based on dermoscopy, can be a valuable tool for diagnosing conditions that cause hair loss and inflammatory scalp disease.
BCC, SCC treatments take advantage of refinements in established techniques and new technology.
There may be an association between atopic dermatitis severity and diagnosis of ocular disease, such as conjunctivitis.
Klint Peebles, MD, FAAD, co-chair of the AAD LGBTQ/GSM Expert Resource Group, discusses how to provide the best care for your gender and sexual minority patients.
Dermavant has submitted a New Drug Application (NDA) to the FDA seeking approval for its novel topical for the treatment of mild, moderate, and severe plaque psoriasis in adult patients.
Revance provides an update on the approval process for its injectable daxibotulinumtoxinA (DAXI) for the treatment of glabellar lines.